QTTB
Bearish signalScored 2026-08-30 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Q32 Bio Inc.
- Nom
- Q32 Bio Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $257.5M
- Employés
- 22
- PDG
- Jodie Pope Morrison
- Site web
- https://www.q32bio.com
- Marché
- ANTXBOLDGBIOINTSITRMNXTC
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 9 845 titres (~163 033,20 $ US)
- Insiders
- Morrison Jodie Pope
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$320,396
Avg sell (VWAP, 90d window) $14.53 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Kalowski Lee | Sell · S | 1,301 | $8.32 | $10,824 | Form 4 |
| 2026-10-06 | Morrison Jodie Pope | Sell · S | 3,221 | $8.32 | $26,798 | Form 4 |
| 2026-10-06 | Violette Shelia M. | Sell · S | 917 | $8.32 | $7,629 | Form 4 |
| 2026-08-25 | Kalowski Lee | Sell · S | 3,972 | $16.56 | $65,776 | Form 4 |
| 2026-08-25 | Morrison Jodie Pope | Sell · S | 9,845 | $16.56 | $163,033 | Form 4 |
| 2026-08-25 | Violette Shelia M. | Sell · S | 2,798 | $16.56 | $46,335 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-30 Drivers: fundamentals. Moteurs : fondamentaux.
QTTB presents a compelling financial turnaround story with strong liquidity (85) and improving fundamentals (75), but the weak catalyst score (35) and low catalyst confidence (0.45) significantly temper the overall…
The first sentence of the analysis written for QTTB on 2026-08-30 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.85 · operating margin 31%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 100.0% | 100.0% | 0.0% | |
| Ebit Margin | 57.5% | 0.0% | 725.5% | -589.8% | 0.0% | |
| Ebitda Margin | 58.3% | 0.0% | 718.0% | -584.2% | 0.0% | |
| Operating Profit Margin | 31.5% | 0.0% | 725.5% | -589.8% | 0.0% | |
| Pretax Profit Margin | 55.5% | 0.0% | 803.3% | -642.7% | 0.0% | |
| Continuous Operations Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Net Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Bottom Line Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Current Ratio | 4.852 | 4.973 | 2.035 | 7.709 | 11.141 | |
| Quick Ratio | 4.852 | 4.973 | 2.035 | 7.709 | 11.141 | |
| Solvency Ratio | 1.529 | -0.545 | -0.232 | -0.823 | -0.892 | |
| Cash Ratio | 4.257 | 4.735 | 1.816 | 1.439 | 6.292 | |
| Price To Earnings Ratio | 1.372 | -0.672 | -2.426 | -6.318 | -20.800 | |
| Price To Earnings Growth Ratio | -0.009 | -0.050 | -0.095 | -0.452 | 0.222 | |
| Forward Price To Earnings Growth Ratio | -0.009 | -0.050 | -0.095 | -0.452 | 0.222 | |
| Price To Earnings Diluted Ratio | 1.372 | -0.523 | -2.426 | -6.318 | -20.800 | |
| Price To Earnings Diluted Growth Ratio | -0.010 | -0.011 | -0.095 | -0.452 | 0.222 | |
| Price To Book Ratio | 0.972 | 5.650 | -0.713 | 1.520 | 4.607 | |
| Price To Sales Ratio | 0.760 | 0.000 | -19.622 | 40.680 | 0.000 | |
| Price To Free Cash Flow Ratio | -1.217 | -0.473 | -6.986 | -20.128 | -6.970 | |
| Price To Operating Cash Flow Ratio | -1.217 | -0.474 | -6.988 | -24.693 | -7.122 | |
| Debt To Assets Ratio | 0.248 | 0.205 | 1.080 | 0.130 | 0.113 | |
| Debt To Equity Ratio | 0.365 | 3.331 | -0.278 | 0.168 | 0.141 | |
| Debt To Capital Ratio | 0.268 | 0.769 | -0.385 | 0.144 | 0.124 | |
| Long Term Debt To Capital Ratio | 0.076 | 0.627 | -0.309 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.470 | 16.270 | -0.257 | 1.290 | 1.248 | |
| Working Capital Turnover Ratio | 0.985 | 0.000 | -0.077 | 0.040 | 0.000 | |
| Operating Cash Flow Ratio | -2.956 | -4.113 | -1.324 | -0.464 | -6.371 | |
| Operating Cash Flow Sales Ratio | -0.624 | 0.000 | 2.808 | -1.647 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.000 | 1.227 | 1.022 | |
| Debt Service Coverage Ratio | 3.900 | -10.608 | -54.754 | -24.931 | -151.191 | |
| Interest Coverage Ratio | 15.365 | -60.093 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.842 | -21.865 | -21.272 | -7.019 | -446.142 | |
| Operating Cash Flow Coverage Ratio | -2.186 | -3.583 | -0.367 | -0.366 | -4.586 | |
| Capital Expenditure Coverage Ratio | 0.000 | -902.867 | -3,735.400 | -4.409 | -45.806 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -902.867 | -3,735.400 | -4.409 | -45.806 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.252 | 0.607 | -3.261 | -6.859 | -19.025 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲100.0% | ▲40.0% |
| Ebit Margin | 57.5% | ▲57.5% | ▲18.9% |
| Ebitda Margin | 58.3% | ▲58.3% | ▲19.9% |
| Operating Profit Margin | 31.4% | ▲31.4% | ▼-2.0% |
| Pretax Profit Margin | 55.5% | ▲55.5% | ▲12.3% |
| Continuous Operations Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Net Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Bottom Line Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Current Ratio | 4.852 | ▼-0.121 | ▼-1.290 |
| Quick Ratio | 4.852 | ▼-0.121 | ▼-1.290 |
| Solvency Ratio | 1.529 | ▲2.074 | ▲1.721 |
| Cash Ratio | 4.257 | ▼-0.478 | ▲0.549 |
| Price To Earnings Ratio | 1.372 | ▲2.044 | ▲7.141 |
| Price To Earnings Growth Ratio | -0.009 | ▲0.040 | ▲0.068 |
| Forward Price To Earnings Growth Ratio | -0.009 | ▲0.040 | ▲0.068 |
| Price To Earnings Diluted Ratio | 1.372 | ▲1.895 | ▲7.111 |
| Price To Earnings Diluted Growth Ratio | -0.010 | ▲0.001 | ▲0.059 |
| Price To Book Ratio | 0.972 | ▼-4.678 | ▼-1.435 |
| Price To Sales Ratio | 0.760 | ▲0.760 | ▼-3.603 |
| Price To Free Cash Flow Ratio | -1.218 | ▼-0.745 | ▲5.937 |
| Price To Operating Cash Flow Ratio | -1.218 | ▼-0.744 | ▲6.881 |
| Debt To Assets Ratio | 0.248 | ▲0.044 | ▼-0.107 |
| Debt To Equity Ratio | 0.365 | ▼-2.965 | ▼-0.380 |
| Debt To Capital Ratio | 0.268 | ▼-0.502 | ▲0.084 |
| Long Term Debt To Capital Ratio | 0.076 | ▼-0.551 | ▼-0.003 |
| Financial Leverage Ratio | 1.470 | ▼-14.800 | ▼-2.534 |
| Working Capital Turnover Ratio | 0.985 | ▲0.985 | ▲0.795 |
| Operating Cash Flow Ratio | -2.956 | ▲1.156 | ▲0.089 |
| Operating Cash Flow Sales Ratio | -0.624 | ▼-0.624 | ▼-0.732 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.050 |
| Debt Service Coverage Ratio | 3.900 | ▲14.508 | ▲51.417 |
| Interest Coverage Ratio | 15.366 | ▲75.458 | ▲24.311 |
| Short Term Operating Cash Flow Coverage Ratio | -4.842 | ▲17.023 | ▲95.386 |
| Operating Cash Flow Coverage Ratio | -2.186 | ▲1.397 | ▲0.031 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲902.867 | ▲937.696 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲902.867 | ▲937.696 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.252 | ▼-0.355 | ▲5.909 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $40.8M | $32.1M | $130.5M | $270.6M | $781.6M | |
| Enterprise value | $7.9M | -$27.0M | $155.7M | $266.5M | $697.2M | |
| EV / Sales | 0.15x | 0.00x | -23.41x | 40.07x | 0.00x | |
| EV / Op. cash flow | -0.23x | 0.40x | -8.34x | -24.32x | -6.35x | |
| EV / Free cash flow | -0.23x | 0.40x | -8.34x | -19.83x | -6.22x | |
| EV / EBITDA | 0.25x | 0.61x | -3.26x | -6.86x | -19.02x | |
| Net debt / EBITDA | -1.05x | 1.33x | -0.53x | 0.10x | 2.30x | |
| Current ratio | 4.85x | 4.97x | 2.04x | 7.71x | 11.14x | |
| Income quality | -1.12x | 1.42x | 0.35x | 0.26x | 1.15x | |
| Graham number | $14 | — | — | — | — | |
| Graham net-net | $2 | -$1 | -$17 | $10 | $10 | |
| Tax burden | 100.0% | 100.0% | 100.6% | 100.1% | 101.5% | |
| Interest burden | 96.4% | 106.1% | 110.7% | 109.0% | 100.9% | |
| Working capital | $43.7M | $65.4M | $14.6M | $158.5M | $174.7M | |
| Invested capital | $49.8M | $72.5M | $22.7M | $180.1M | $192.5M | |
| Return on assets | 48.3% | -51.7% | -114.2% | -18.7% | -17.7% | |
| Operating ROA | 21.9% | -94.8% | -34.9% | -17.8% | -15.4% | |
| Return on tangible assets | 48.3% | -51.7% | -114.2% | -18.7% | -17.7% | |
| Return on equity | 71.0% | -841.1% | 29.4% | -24.1% | -22.1% | |
| Return on invested capital | 29.5% | -83.1% | -140.4% | -18.9% | -18.8% | |
| Return on capital employed | 33.5% | -87.1% | -146.5% | -19.0% | -18.9% | |
| Earnings yield | 73.0% | -148.9% | -41.2% | -15.8% | -4.8% | |
| Free cash flow yield | -82.1% | -211.4% | -14.3% | -5.0% | -14.3% | |
| Capex / Op. cash flow | 0.0% | -0.1% | -0.0% | -22.7% | -2.2% | |
| Capex / Depreciation | 0.0% | 15.4% | 1.0% | 671.6% | 25.1% | |
| Capex / Sales | 0.0% | 0.0% | -0.1% | 37.4% | 0.0% | |
| SG&A / Sales | 32.9% | 0.0% | -148.5% | 151.3% | 0.0% | |
| R&D / Sales | 35.6% | 0.0% | -477.1% | 538.5% | 0.0% | |
| Stock comp / Sales | 9.8% | 0.0% | -21.5% | 18.6% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | -41d | 58d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | -41d | 58d | 0d | |
| Cash conversion cycle | 0d | 0d | -41d | 58d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-17 Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 2026-08-05 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H''2027 subject to planned regulatory discussions later this year -- -- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development -- -- Completed $200 million public offering in July 2026 -- -- Cash and cash equivalents of $106.3 million as of June 30, 2026, combined with proceeds from July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from planned registration-directed program -- WALTHAM, Mass., Aug. 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.
- 2026-07-31 Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-07-23 Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL''s Phase 2 efficacy readout for ABCL635 in Q3 and ACOG''s Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
- 2026-07-20 Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-07-17 Q32 Bio: Bempikibart''s Progress Keeps Me Bullish Q32 Bio''s Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits appear to last well after finishing treatment. These factors could help differentiate Bempikibart from other continuously dosed JAK inhibitors.
- 2026-07-15 Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-07-14 Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant.
- 2026-07-13 Why Q32 Bio Stock Skyrocketed Today The biotech is advancing a potential treatment for a common autoimmune disease.
- 2026-07-13 Q32 Bio: ''Strong Buy'' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction and up to 40% of severe AA patients reaching SALT 20. Bempikibart''s improved safety, durable efficacy, and maintenance dosing potential position it as a first-line alternative to JAK inhibitors.